Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Angiotensin II is a peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock. Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure.
- Mechanism
- Curator reviewed · 1 reference
As part of the renin-angiotensin-aldosterone-system (RAAS), angiotensin II raises blood pressure by vasoconstriction, increased aldosterone release by the adrenal zona glomerulosa, sodium and water reabsorption in the proximal tubular cells, and vasopressin secretion
The direct action of angiotensin II on surrounding vessel walls is facilitated by binding to the G-protein-coupled angiotensin II receptor type 1 (AT-1) on vascular smooth muscle cells, which stimulates Ca2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction that results in vasoconstriction.
The RAAS is ultimately regulated by a negative feedback effect of angiotensin II on renin production by the juxtaglomerular cells of the renal afferent arteriole. Unresuscitated septic shock associated with marked hypovolemia, extracellular fluid volume depletion, decreased cardiac output, low arterial blood pressure and decreased systemic vascular resistance causes an increase in renin secretion by the juxtaglomerular cells, resulting in elevated angiotensin II plasma levels and an increased secretion of aldosterone from the adrenal cortex. Angiotensin II binding to AT-1 receptors causes dose-dependent vasoconstriction of both afferent and efferent glomerular arterioles. The most pronounced effect of angiotensin II results on efferent arterioles, resulting in reduced renal blood flow and increased glomerular filtration pressure.
- Primary indication
- Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock.Curator reviewed · 1 structured indication
- First approval
- United States, 2018 · European Union, 2021
- Also known as
- Angiotensin · Angiotensin II (human) · Angiotensin-II · Angiotonin · Human angiotensin II
- Code names
- LJPC-501
- Brand names
- Giapreza
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Angiotensin II, and which of those have an active Phase 3 trial?